Vixarelimab has been designed to target oncostatin M receptor beta (OSMRβ) that mediates the interleukin-31 (IL-31) and oncostatin M (OSM) signalling. IL-31 and OSM are two important cytokines
The post Roche, Genentech sign license deal with Kiniksa for vixarelimab appeared first on Pharmaceutical Business review.